Who
Paul R. Fonteyne
Director
Company insider
Files Form 4 as: Director, Apnimed; Director, Amylyx Pharmaceuticals; Director, Apellis Pharmaceuticals; Director, Covetrus; Director, Gelesis Holdings; Director, Amag Pharmaceuticals; Director, Adicet Bio.
In numbers
- Trades disclosed
- 81
- Buys
- 3
- Sells
- 0
- Bought
- $350K
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 8 May 2019
- Last trade
- 3 Aug 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —51,890 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,890 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —51,890 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,890 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —30,666 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,554 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,441 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —27,600 | filing |
News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Sells 30,000 Shares of StockAMLX · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Paul R. Fonteyne; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.